Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Recruiting 13Active not recruiting 11Completed 10Terminated 4Not yet recruiting 3Withdrawn 2Unknown 2

Sponsor Class

OTHER 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 27Gynecologic 4Genitourinary 3Breast 2Thoracic 1Sarcoma 1Other solid neoplasm 1Head & Neck 1

Conditions

Carcinoma, Renal Cell 3Clear-cell metastatic renal cell carcinoma 1

Interventions

Gemcitabine 13Radiotherapy 12Androgen Antagonists 12Specimen Handling 11Magnetic Resonance Spectroscopy 10pembrolizumab 9Nivolumab 8toripalimab 7darolutamide 7Drug Therapy 7Radiosurgery 6Docetaxel 6Cystectomy 6enzalutamide 5apalutamide 5Mitomycin 5Cisplatin 5Axitinib 5Abiraterone Acetate 5disitamab vedotin 4cabozantinib 4abiraterone 4Pluvicto 4Cyclophosphamide 4tislelizumab 3lenvatinib 3fludarabine 3cemiplimab 3Sunitinib 3Standard of Care 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × lenvatinib × Genitourinary × Clear all
NCT07460206 2026-03-10

PRELUDE

Gruppo Oncologico Italiano di Ricerca Clinica

Phase 2 Not yet recruiting
108 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT07383441 2026-02-03

Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer

SWOG Cancer Research Network

Phase 3 Not yet recruiting
718 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT07277972 2025-12-11

Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting
36 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡